Expertise in
21
conditions

Selim K. Corbacioglu

Franz Josef Strauss Allee 11, 
Regensburg, BY, DE 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
21
conditions
Franz Josef Strauss Allee 11, 
Regensburg, BY, DE 

Overview

Selim Corbacioglu practices practicing medicine in Regensburg, Germany.

Mr. Corbacioglu is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Hepatic Venoocclusive Disease with Immunodeficiency, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 167 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Franz Josef Strauss Allee 11, Regensburg, BY 93053, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)
Enrollment Status: Recruiting
Publish Date: February 07, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma
Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma
Enrollment Status: Completed
Publish Date: October 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

166 Total Publications

Gene therapy for sickle cell disease: Practice recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy.
Gene therapy for sickle cell disease: Practice recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy.
Journal: Transplantation and cellular therapy
Published: March 16, 2026

Frequently Asked Questions about Selim K. Corbacioglu

Is Selim K. Corbacioglu a top-rated expert for Hepatic Venoocclusive Disease with Immunodeficiency?

MediFind is an objective health platform that identifies experts based on real-world data. Selim K. Corbacioglu is classified as an Elite expert for Hepatic Venoocclusive Disease with Immunodeficiency, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Selim K. Corbacioglu participate in research or clinical trials?

Yes. Selim K. Corbacioglu has published 166 articles and abstracts on conditions like Hepatic Venoocclusive Disease with Immunodeficiency. You can view a list of Selim K. Corbacioglu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Corbacioglu's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Advanced Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile